ADMA BIOLOGICS, INC. Proceeds from Issuance of Debt
ADMA BIOLOGICS, INC. (ADMA) reported Proceeds from Issuance of Debt of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2019-03-13
- ADMA BIOLOGICS, INC. proceeds from issuance of debt for the quarter ending 2018-12-31 was $0.00.
- ADMA BIOLOGICS, INC. proceeds from issuance of debt for the quarter ending 2018-09-30 was $0.00.
- ADMA BIOLOGICS, INC. proceeds from issuance of debt for the quarter ending 2018-06-30 was -$15.00M.
- ADMA BIOLOGICS, INC. proceeds from issuance of debt for the quarter ending 2018-03-31 was $15.00M.
- ADMA BIOLOGICS, INC. proceeds from issuance of debt for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- ADMA BIOLOGICS, INC. proceeds from issuance of debt for fiscal 2017 was $15.00M.
- ADMA BIOLOGICS, INC. proceeds from issuance of debt for fiscal 2016 was $0.00.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $0.00 derived: sum of 2 quarters · filed 2019-03-13 | -$15.00M derived: sum of 3 quarters · filed 2019-03-13 | $0.00 10-K · filed 2019-03-13 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$15.00M derived: sum of 2 quarters · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 | $0.00 derived: sum of 4 quarters · filed 2019-03-13 |
| 2018-06-30 | -$15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $0.00 10-Q · filed 2018-08-10 | $0.00 derived: sum of 3 quarters · filed 2019-03-13 | $0.00 derived: sum of 4 quarters · filed 2019-03-13 |
| 2018-03-31 | $15.00M 10-Q · filed 2018-05-14 | $15.00M derived: sum of 2 quarters · filed 2019-03-13 | $15.00M derived: sum of 3 quarters · filed 2019-03-13 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $0.00 derived: sum of 2 quarters · filed 2019-03-13 | $15.00M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $15.00M 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $15.00M 10-Q · filed 2018-08-10 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $0.00 derived: sum of 2 quarters · filed 2018-03-29 | $0.00 10-K · filed 2018-03-29 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $0.00 10-Q · filed 2017-11-03 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |